Earnings Call Summary | Cytokinetics(CYTK.US) Q1 2025 Earnings Conference
Cytokinetics Targets Aficamten Approval With Extended PDUFA Timeline and Growing Clinical Data
Cytokinetics Reports Q1 2025 Financials and Strategic Progress
Cytokinetics Shares Fall as Q1 Revenue Misses Estimates
Earnings Flash (CYTK) Cytokinetics Q1 Revenue $1.6 Million Vs. FactSet Est. $2.5 Million
Cytokinetics | 10-Q: Q1 2025 Earnings Report
CYTOKINETICS Earnings Results: $CYTK Reports Quarterly Earnings
Express News | Cytokinetics Shares Drop 4.2% in Extended Trading After Posting Quarterly Results
Cytokinetics Reports Q1 EPS ($1.36), Consensus ($1.36)
Cytokinetics Maintaining Its Full Yr 2025 Fincl Guidance >CYTK
Cytokinetics: Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 >CYTK
Cytokinetics: Topline Results From MAPLE-HCM Expected in May >CYTK
Cytokinetics: PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to Dec 26 >CYTK
Cytokinetics | 8-K: CYTOKINETICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Press Release: Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update
Cytokinetics 1Q Loss $161.4M >CYTK
Express News | Cytokinetics Q1 Operating Expenses USD 157.21 Million
Express News | Cytokinetics Q1 Basic EPS USD -1.36
Express News | Cytokinetics Drops After Volume Spike, Last off 6.3%
Earnings Scheduled For May 6, 2025